Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.34 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289916 | 0.88 | KMT2A (0.46) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 | |
| SCHEMBL8654771 | 0.85 | KMT2A (0.51) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 | |
| SCHEMBL1566660 | 0.84 | KMT2A (0.44) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 | |
| SCHEMBL28848988 | 0.80 | KMT2A (0.46) | KMT2ALMNASMN1; SMN2LPAR1PDE4B | |
| SCHEMBL19922118 | 0.78 | LMNA (0.40) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 | |
| SCHEMBL175703 | 0.77 | DGAT1 (0.42) | KMT2A | |
| SCHEMBL11061926 | 0.76 | KMT2A (0.45) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 | |
| SCHEMBL1566662 | 0.74 | KMT2A (0.48) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 | |
| SCHEMBL1566952 | 0.74 | KMT2A (0.48) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 | |
| SCHEMBL29824483 | 0.74 | KMT2A (0.56) | KMT2ALMNASMN1; SMN2LPAR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100011656-A1 | USE OF RYLENES AS MARKERS FOR LIQUIDS | BASF SE (DE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100011656-A1 | USE OF RYLENES AS MARKERS FOR LIQUIDS | RPL22, PROX1, RPL29 | KMT2A 2164/4885LMNA 3892/4885SMN1; SMN2 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.